CFDA Granted Approval of Phase I-III Clinical Trials for Sirotinib (XZP - 5491)

Clinical Trials of Sirotinib (XZP - 5491) by CFDA with the Approval Numbers of 2016L06493 and 2016L06497. ...

Detail >
2016-08-04 15:252013-12-24 9:50
Phase II/ III Clinical Trials of Imigliptin Hydrochloride (KBP-3853) have been approved by CFDA; the Clinic...
2015-08-26 08:202013-12-24 9:50
Dr. Frank Wu (CEO, Shandong Xuanzhu Pharma Co., Ltd. and specially appointed National Thousand Talents Program...
2015-08-07 16:412013-12-24 9:50
CFDA approved our IND application of Pirotinib Hydrochloride (KBP-5209) today and more importantly granted us a...
2015-07-17 14:362013-12-24 9:50
IND filing of Sirotinib (XZP-5491), submitted at the end of June 2015, has been approved by CFDA (The filing numbers are CXHL1501499 and CXHL1501499).
2015-07-17 14:322013-12-24 9:50
On May 30th, the 2nd basketball tournament was held at XuanZhu. Seven teams from different divisions fough...
2015-06-16 08:172013-12-24 9:50
Pirotinib, a proprietary oncology drug developed by XuanZhu Pharma, has achieved a significant milestone - The fir...

Email | Terms of Use | Contact us

2014版權?軒竹醫藥科技有限公司保留所有權利 魯ICP備09030169號

青海快3十大规律 三板股票涨跌幅 易投配资 浙江体彩6十1 一分钟开奖投注手机app 湖北11选五的走势图彩经网 点石策略 广东36选7开奖查询 青海体彩11任选5 北京快乐8在线网页计划 亿鑫配资